Royal Bank Of Canada Issues Pessimistic Forecast for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price target cut by Royal Bank Of Canada from $18.00 to $14.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target suggests a potential upside of 181.86% from the company’s previous close.

Several other equities analysts have also commented on CATX. Piper Sandler initiated coverage on Perspective Therapeutics in a research note on Thursday, February 19th. They issued an “overweight” rating and a $16.00 target price for the company. HC Wainwright lifted their price target on Perspective Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, January 30th. UBS Group reaffirmed a “buy” rating and set a $7.00 price objective (down from $18.00) on shares of Perspective Therapeutics in a research note on Friday, November 21st. B. Riley Financial decreased their target price on shares of Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Finally, BTIG Research reissued a “buy” rating and issued a $14.00 target price on shares of Perspective Therapeutics in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $12.13.

Perspective Therapeutics Trading Down 4.8%

Shares of CATX traded down $0.25 on Tuesday, hitting $4.97. 331,736 shares of the stock traded hands, compared to its average volume of 3,784,240. Perspective Therapeutics has a 1 year low of $1.60 and a 1 year high of $6.16. The stock’s 50 day moving average is $4.22 and its two-hundred day moving average is $3.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.66 and a current ratio of 8.66.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.51) earnings per share for the quarter. Perspective Therapeutics had a negative net margin of 9,841.86% and a negative return on equity of 40.03%. The business had revenue of $0.04 million during the quarter. On average, research analysts predict that Perspective Therapeutics will post -0.88 earnings per share for the current year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of large investors have recently modified their holdings of CATX. Opaleye Management Inc. acquired a new position in shares of Perspective Therapeutics in the 4th quarter valued at about $3,257,000. Patient Square Capital LP increased its position in Perspective Therapeutics by 224.3% during the 4th quarter. Patient Square Capital LP now owns 1,132,815 shares of the company’s stock worth $3,115,000 after purchasing an additional 783,492 shares in the last quarter. Bank of America Corp DE increased its position in Perspective Therapeutics by 139.9% during the 3rd quarter. Bank of America Corp DE now owns 785,823 shares of the company’s stock worth $2,695,000 after purchasing an additional 458,323 shares in the last quarter. Marshall Wace LLP purchased a new position in Perspective Therapeutics in the fourth quarter valued at approximately $1,119,000. Finally, JPMorgan Chase & Co. lifted its position in Perspective Therapeutics by 118.4% during the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock valued at $2,573,000 after buying an additional 405,612 shares in the last quarter. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.